Novartis rides IgAN trioka to 2 trial wins in rare kidney di

Novartis is eyeing an FDA filing for a second drug in immunoglobulin A nephropathy (IgAN), as the Swiss pharma goes all-in on the rare autoimmune kidney disease from three different angles.

Related Keywords

Switzerland , Swiss , Shreeram Aradhye , Travere Filspari , Willima Blair , William Blair , European Renal Association Congress , Novartis , European Renal Association , Travere Therapeutic , Leerink Partners ,